In fact initial studies of the technology showed 94% of the inhaled dose was found in the systemic circulation.
This massive increase in efficiency, should lead to better treatment, reducing pressure on healthcare services, and most importantly improved quality of life for sufferers.
*33% of the dispensed dose is reaching the target area of the lung. The rest is deposited in the mouth and upper airways where it is ineffective and can cause adverse effects like oral candidiasis.
Copyright © 2023 Athos Medical Technology - All Rights Reserved.